Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19 (STOP Severe COVID-19)

NCT04634799 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT04634799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04634799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19 (STOP Severe COVID-19)
Lead sponsor
Northwestern University
Phase
Phase 1/2
Overall status
Terminated
Start date
January 8, 2021
Completion date
August 30, 2021
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19